BioNet News 12 Dec 2023 Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines Highlights • Recombinant pertussis vaccine is safe for both mother and newborn. • There is effective transplacental antibody transfer to… Supachai
BioNet News 22 Jun 2023 A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women Highlights • Recombinant acellular pertussis vaccine is safe and immunogenic in pregnant women. • Vaccine formulations containing PTgen were non-inferior… Supachai
BioNet News 05 Apr 2022 A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age A phase 2 randomized-controlled safety and immunogenicity trial evaluating different doses of recombinant acellular pertussis vaccine containing genetically-inactivated pertussis toxin… Pantitra
Biotech News, Covid-19 24 Sep 2021 Scancell picks PharmaJet’s needle-free injection systems to deliver COVID-19 vaccine candidates Scancell selected Golden, Colorado-based PharmaJet’s devices to administer two SARS-CoV-2 DNA-based vaccine candidates, SCOV1 and SCOV2. The vaccines will be… Supachai
BioNet News 23 Jul 2021 Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines Recombinant pertussis vaccines inducing long-lasting immune responses could help to control the rise in pertussis. We here report on persisting… Pantitra
Biotech News, Covid-19 27 Jun 2021 Is a needle-free Covid-19 vaccination possible? The University of Texas Hexapro vaccine candidate, delivered via the UQ-developed and Vaxxas-commercialised high-density microarray patch (HD-MAP), provided protection against… Supachai
BioNet News 05 Dec 2020 Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen®) vaccine for immunization of adolescents and adults in Thailand A new generation of recombinant acellular pertussis vaccine containing genetically inactivated pertussis toxin (PTgen) was licensed as a monovalent pertussis… Pantitra
